Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses.
作者信息
Zeng Lei-Ping, Ge Xing-Yi, Peng Cheng, Tai Wanbo, Jiang Shibo, Du Lanying, Shi Zheng-Li
机构信息
CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, 10021, USA.
出版信息
Sci China Life Sci. 2017 Dec;60(12):1399-1402. doi: 10.1007/s11427-017-9189-3. Epub 2017 Nov 10.
Abstract
摘要
相似文献
1
Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses.针对蝙蝠类严重急性呼吸综合征冠状病毒的严重急性呼吸综合征冠状病毒特异性抗体的交叉中和作用。
Sci China Life Sci. 2017 Dec;60(12):1399-1402. doi: 10.1007/s11427-017-9189-3. Epub 2017 Nov 10.
2
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.人类单克隆 SARS-CoV 抗体对 SARS-CoV-2 的交叉中和作用。
Nature. 2020 Jul;583(7815):290-295. doi: 10.1038/s41586-020-2349-y. Epub 2020 May 18.
3
Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.鉴定针对 SARS-CoV RBD 的单克隆抗体，这些抗体对 SARS-CoV-2 具有交叉反应性或中和活性。
Antiviral Res. 2020 Jul;179:104820. doi: 10.1016/j.antiviral.2020.104820. Epub 2020 May 13.
4
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.新冠病毒和非典病毒感染之间的交叉反应性抗体反应。
Cell Rep. 2020 Jun 2;31(9):107725. doi: 10.1016/j.celrep.2020.107725. Epub 2020 May 18.
5
Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibody.严重急性呼吸综合征冠状病毒刺突糖蛋白中第1128位天冬氨酸的替换介导了对靶向S2结构域的中和单克隆抗体的逃逸。
PLoS One. 2014 Jul 14;9(7):e102415. doi: 10.1371/journal.pone.0102415. eCollection 2014.
6
Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.MW06 是一种人源单克隆抗体，对 SARS-CoV-2 和 SARS-CoV 均具有交叉中和活性。
MAbs. 2021 Jan-Dec;13(1):1953683. doi: 10.1080/19420862.2021.1953683.
7
Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.严重急性呼吸综合征冠状病毒刺突蛋白的受体结合域包含多个构象依赖性表位，这些表位可诱导产生高效中和抗体。
J Immunol. 2005 Apr 15;174(8):4908-15. doi: 10.4049/jimmunol.174.8.4908.
8
Broad neutralization of SARS-related viruses by human monoclonal antibodies.人类单克隆抗体对 SARS 相关病毒的广泛中和作用。
Science. 2020 Aug 7;369(6504):731-736. doi: 10.1126/science.abc7424. Epub 2020 Jun 15.
9
SARS-like WIV1-CoV poised for human emergence.类似SARS的WIV1冠状病毒随时可能在人类中出现。
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3048-53. doi: 10.1073/pnas.1517719113. Epub 2016 Mar 14.
10
Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.SARS-CoV-2 刺突蛋白中与 ACE2 和中和抗体相互作用的受体结合基序的关键残基。
Cell Mol Immunol. 2020 Jun;17(6):621-630. doi: 10.1038/s41423-020-0458-z. Epub 2020 May 15.
引用本文的文献
1
Characterization of a mouse-adapted strain of bat severe acute respiratory syndrome-related coronavirus.一种适应鼠类的蝙蝠严重急性呼吸综合征相关冠状病毒的特性描述。
J Virol. 2023 Sep 28;97(9):e0079023. doi: 10.1128/jvi.00790-23. Epub 2023 Aug 21.
2
ACE2-Independent Bat Sarbecovirus Entry and Replication in Human and Bat Cells.ACE2 非依赖性蝙蝠 SARS 样冠状病毒在人源和蝙蝠细胞中的进入和复制。
mBio. 2022 Dec 20;13(6):e0256622. doi: 10.1128/mbio.02566-22. Epub 2022 Nov 21.
3
Inactivated SARS-CoV-2 Vaccine Shows Cross-Protection against Bat SARS-Related Coronaviruses in Human ACE2 Transgenic Mice.灭活的 SARS-CoV-2 疫苗在人 ACE2 转基因小鼠中显示出对蝙蝠 SARS 相关冠状病毒的交叉保护作用。
J Virol. 2022 Apr 27;96(8):e0016922. doi: 10.1128/jvi.00169-22. Epub 2022 Mar 28.
4
Harnessing immunological targets for COVID-19 immunotherapy.利用免疫靶点进行新冠病毒免疫治疗。
Future Virol. 2021 Jul. doi: 10.2217/fvl-2021-0048. Epub 2021 Aug 9.
5
Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review.严重急性呼吸综合征冠状病毒2（COVID-19）的前沿治疗方法与疫苗策略：综述
Iran J Public Health. 2020 Oct;49(Suppl 1):18-29. doi: 10.18502/ijph.v49iS1.3666.
6
Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2.治疗和预防 COVID-19 大流行的策略：中和 SARS-CoV-2 的免疫治疗方法综述。
Int J Biol Macromol. 2021 Sep 1;186:490-500. doi: 10.1016/j.ijbiomac.2021.07.013. Epub 2021 Jul 5.
7
Characteristics of Angiotensin I-converting enzyme 2, type II transmembrane serine protease 2 and 4 in tree shrew indicate it as a potential animal model for SARS-CoV-2 infection.树鼩中血管紧张素 I 转换酶 2、II 型跨膜丝氨酸蛋白酶 2 和 4 的特征表明其可能成为 SARS-CoV-2 感染的动物模型。
Bioengineered. 2021 Dec;12(1):2836-2850. doi: 10.1080/21655979.2021.1940072.
8
Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative.安全有效的 SARS-CoV-2 亚单位疫苗开发的关键考虑因素：一种基于肽的疫苗替代方案。
Adv Sci (Weinh). 2021 Aug;8(16):e2100985. doi: 10.1002/advs.202100985. Epub 2021 Jun 27.
9
identification of RBD subdomain of spike protein from Pro-Thr for applications in vaccine development against SARS-CoV2.从脯氨酸-苏氨酸处鉴定刺突蛋白的RBD亚结构域，用于抗SARS-CoV-2疫苗开发。
J Mol Struct. 2021 Sep 15;1240:130534. doi: 10.1016/j.molstruc.2021.130534. Epub 2021 Apr 30.
10
Epidemiology of coronaviruses, genetics, vaccines, and scenario of current pandemic of coronavirus diseases 2019 (COVID-19): a fuzzy set approach.冠状病毒的流行病学、遗传学、疫苗及 2019 年冠状病毒病（COVID-19）大流行的现状：模糊集方法。
Hum Vaccin Immunother. 2021 May 4;17(5):1296-1303. doi: 10.1080/21645515.2020.1798697. Epub 2021 Mar 15.
本文引用的文献
1
Bat Severe Acute Respiratory Syndrome-Like Coronavirus WIV1 Encodes an Extra Accessory Protein, ORFX, Involved in Modulation of the Host Immune Response.蝙蝠严重急性呼吸综合征样冠状病毒WIV1编码一种额外的辅助蛋白ORFX，参与宿主免疫反应的调节。
J Virol. 2016 Jun 24;90(14):6573-6582. doi: 10.1128/JVI.03079-15. Print 2016 Jul 15.
2
Bat origin of human coronaviruses.人类冠状病毒的蝙蝠起源
Virol J. 2015 Dec 22;12:221. doi: 10.1186/s12985-015-0422-1.
3
Identification of immunogenic determinants of the spike protein of SARS-like coronavirus.鉴定 SARS 样冠状病毒刺突蛋白的免疫原决定簇。
Virol Sin. 2013 Apr;28(2):92-6. doi: 10.1007/s12250-013-3292-y. Epub 2013 Apr 11.
4
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.人源单克隆抗体对严重急性呼吸综合征冠状病毒分离株的强效交叉反应中和作用。
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12123-8. doi: 10.1073/pnas.0701000104. Epub 2007 Jul 9.
5
SARS vaccine development.严重急性呼吸综合征疫苗研发
Emerg Infect Dis. 2005 Jul;11(7):1016-20. doi: 10.3201/1107.050219.
6
Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.严重急性呼吸综合征冠状病毒刺突蛋白的受体结合域包含多个构象依赖性表位，这些表位可诱导产生高效中和抗体。
J Immunol. 2005 Apr 15;174(8):4908-15. doi: 10.4049/jimmunol.174.8.4908.
7
A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2.严重急性呼吸综合征冠状病毒S蛋白的一个193个氨基酸的片段可有效结合血管紧张素转换酶2。
J Biol Chem. 2004 Jan 30;279(5):3197-201. doi: 10.1074/jbc.C300520200. Epub 2003 Dec 11.
8
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.血管紧张素转换酶2是严重急性呼吸综合征冠状病毒的功能性受体。
Nature. 2003 Nov 27;426(6965):450-4. doi: 10.1038/nature02145.
Zotero 插件